Fan Jing-Qi, Xu Zi-Qiao, Chen Yuan-Yuan, Lu Wei-Jing, Xie Xiao-Yan, Wang Yu-Ting, Zhuang Li-Xing
Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong, China.
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong, China.
Evid Based Complement Alternat Med. 2022 Feb 9;2022:5180193. doi: 10.1155/2022/5180193. eCollection 2022.
Parkinson's disease anxiety (PDA) is a nonmotor symptom of Parkinson's disease (PD) that is often neglected. PDA poses a far-reaching challenge to the treatment of PD. Acupuncture could be successful in the treatment of PDA. However, the evidence for this is still limited. We propose a two-stage clinical trial. In stage 1, a total of 70 volunteers with PDA will be randomly assigned to either acupuncture (manual acupuncture) or control group (sham acupuncture) in a 1 : 1 ratio. Treatments will be performed for four weeks. The change in the Hamilton Rating Scale for Anxiety (HAMA) score from baseline to week 4 and week 12 will be the primary outcome. The levels of adrenocorticotropic hormone (ACTH), cortisol (CORT), serotonin (5-HT), and corticotropin-releasing factor (CRH) in the patients' serum and the scores on the Hoehn-Yahr Rating Scale and the Unified Parkinson's Disease Rating Scale (UPDRS) will all be considered among the secondary outcomes. Participants will be followed up until week 12. In stage 2, a total of 82 volunteers with PDA will be randomly assigned to either an acupuncture (manual acupuncture) or a control group (anti-Parkinson drugs only) in a 1 : 1 ratio. HAMA score will be the primary outcome. Universality, feasibility and cost effectiveness, Hoehn-Yahr Rating Scale, UPDRS, and serological indicators will be secondary outcomes. Participants will be followed up until week 4. The statistical analysis will include all the allocated individuals. The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine's Research Ethical Committee authorized this procedure, and the trial is registered with ChiCTR2100047253.
帕金森病焦虑症(PDA)是帕金森病(PD)的一种非运动症状,常被忽视。PDA对PD的治疗构成了深远挑战。针灸可能成功治疗PDA。然而,这方面的证据仍然有限。我们提出一项两阶段临床试验。在第一阶段,总共70名PDA志愿者将按1∶1的比例随机分配到针灸组(手针)或对照组(假针灸)。治疗将进行四周。从基线到第4周和第12周汉密尔顿焦虑量表(HAMA)评分的变化将作为主要结局。患者血清中促肾上腺皮质激素(ACTH)、皮质醇(CORT)、血清素(5-羟色胺,5-HT)和促肾上腺皮质激素释放因子(CRH)的水平以及Hoehn-Yahr分级量表和统一帕金森病评定量表(UPDRS)的评分都将被视为次要结局。参与者将被随访至第12周。在第二阶段,总共82名PDA志愿者将按1∶1的比例随机分配到针灸组(手针)或对照组(仅使用抗帕金森病药物)。HAMA评分将作为主要结局。普遍性、可行性和成本效益、Hoehn-Yahr分级量表、UPDRS和血清学指标将作为次要结局。参与者将被随访至第4周。统计分析将包括所有分配的个体。广州中医药大学第一附属医院研究伦理委员会批准了该程序,该试验已在中国临床试验注册中心注册,注册号为ChiCTR2100047253。